NDAOPHTHALMICSOLUTION/DROPS
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
VIZZ (aceclidine) by LENZ Therapeutics. Approved for presbyopia. First approved in 2025.
Drug data last refreshed 20h ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (2)
Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia
Started Aug 2022
59 enrolled
PresbyopiaRefractive ErrorsEye Diseases
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
Started May 2022
68 enrolled
PresbyopiaRefractive ErrorsEye Diseases
Worked on VIZZ at LENZ Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.